148 related articles for article (PubMed ID: 19823047)
1. Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
Yang SX; Kummar S; Steinberg SM; Murgo AJ; Gutierrez M; Rubinstein L; Nguyen D; Kaur G; Chen AP; Giranda VL; Tomaszewski JE; Doroshow JH;
Cancer Biol Ther; 2009 Nov; 8(21):2004-9. PubMed ID: 19823047
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells.
Feng X; Koh DW
Int J Oncol; 2013 Feb; 42(2):749-56. PubMed ID: 23254695
[TBL] [Abstract][Full Text] [Related]
3. Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells.
Ji J; Kinders RJ; Zhang Y; Rubinstein L; Kummar S; Parchment RE; Tomaszewski JE; Doroshow JH
PLoS One; 2011; 6(10):e26152. PubMed ID: 22028822
[TBL] [Abstract][Full Text] [Related]
4. Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.
Kinders RJ; Hollingshead M; Khin S; Rubinstein L; Tomaszewski JE; Doroshow JH; Parchment RE;
Clin Cancer Res; 2008 Nov; 14(21):6877-85. PubMed ID: 18980982
[TBL] [Abstract][Full Text] [Related]
5. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
Kummar S; Kinders R; Gutierrez ME; Rubinstein L; Parchment RE; Phillips LR; Ji J; Monks A; Low JA; Chen A; Murgo AJ; Collins J; Steinberg SM; Eliopoulos H; Giranda VL; Gordon G; Helman L; Wiltrout R; Tomaszewski JE; Doroshow JH
J Clin Oncol; 2009 Jun; 27(16):2705-11. PubMed ID: 19364967
[TBL] [Abstract][Full Text] [Related]
6. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
[TBL] [Abstract][Full Text] [Related]
7. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
LoRusso PM; Li J; Burger A; Heilbrun LK; Sausville EA; Boerner SA; Smith D; Pilat MJ; Zhang J; Tolaney SM; Cleary JM; Chen AP; Rubinstein L; Boerner JL; Bowditch A; Cai D; Bell T; Wolanski A; Marrero AM; Zhang Y; Ji J; Ferry-Galow K; Kinders RJ; Parchment RE; Shapiro GI
Clin Cancer Res; 2016 Jul; 22(13):3227-37. PubMed ID: 26842236
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
Kummar S; Chen A; Ji J; Zhang Y; Reid JM; Ames M; Jia L; Weil M; Speranza G; Murgo AJ; Kinders R; Wang L; Parchment RE; Carter J; Stotler H; Rubinstein L; Hollingshead M; Melillo G; Pommier Y; Bonner W; Tomaszewski JE; Doroshow JH
Cancer Res; 2011 Sep; 71(17):5626-34. PubMed ID: 21795476
[TBL] [Abstract][Full Text] [Related]
9. The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy.
Nowsheen S; Bonner JA; Yang ES
Radiother Oncol; 2011 Jun; 99(3):331-8. PubMed ID: 21719137
[TBL] [Abstract][Full Text] [Related]
10. Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
Muñoz-Gámez JA; López Viota J; Barrientos A; Carazo Á; Sanjuán-Nuñez L; Quiles-Perez R; Muñoz-de-Rueda P; Delgado Á; Ruiz-Extremera Á; Salmerón J
Liver Int; 2015 Apr; 35(4):1430-41. PubMed ID: 24821649
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.
Schaefer NG; James E; Wahl RL
Nucl Med Commun; 2011 Nov; 32(11):1046-51. PubMed ID: 21956491
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression.
Mariano G; Ricciardi MR; Trisciuoglio D; Zampieri M; Ciccarone F; Guastafierro T; Calabrese R; Valentini E; Tafuri A; Del Bufalo D; Caiafa P; Reale A
Oncotarget; 2015 Jun; 6(17):15008-21. PubMed ID: 25938539
[TBL] [Abstract][Full Text] [Related]
13. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.
Vilar E; Bartnik CM; Stenzel SL; Raskin L; Ahn J; Moreno V; Mukherjee B; Iniesta MD; Morgan MA; Rennert G; Gruber SB
Cancer Res; 2011 Apr; 71(7):2632-42. PubMed ID: 21300766
[TBL] [Abstract][Full Text] [Related]
14. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
Donawho CK; Luo Y; Luo Y; Penning TD; Bauch JL; Bouska JJ; Bontcheva-Diaz VD; Cox BF; DeWeese TL; Dillehay LE; Ferguson DC; Ghoreishi-Haack NS; Grimm DR; Guan R; Han EK; Holley-Shanks RR; Hristov B; Idler KB; Jarvis K; Johnson EF; Kleinberg LR; Klinghofer V; Lasko LM; Liu X; Marsh KC; McGonigal TP; Meulbroek JA; Olson AM; Palma JP; Rodriguez LE; Shi Y; Stavropoulos JA; Tsurutani AC; Zhu GD; Rosenberg SH; Giranda VL; Frost DJ
Clin Cancer Res; 2007 May; 13(9):2728-37. PubMed ID: 17473206
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.
Albert JM; Cao C; Kim KW; Willey CD; Geng L; Xiao D; Wang H; Sandler A; Johnson DH; Colevas AD; Low J; Rothenberg ML; Lu B
Clin Cancer Res; 2007 May; 13(10):3033-42. PubMed ID: 17505006
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibitors attenuate chemotherapy-induced painful neuropathy.
Brederson JD; Joshi SK; Browman KE; Mikusa J; Zhong C; Gauvin D; Liu X; Shi Y; Penning TD; Shoemaker AR; Giranda VL
J Peripher Nerv Syst; 2012 Sep; 17(3):324-30. PubMed ID: 22971094
[TBL] [Abstract][Full Text] [Related]
18. Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
Niu J; Scheuerell C; Mehrotra S; Karan S; Puhalla S; Kiesel BF; Ji J; Chu E; Gopalakrishnan M; Ivaturi V; Gobburu J; Beumer JH
J Clin Pharmacol; 2017 Aug; 57(8):977-987. PubMed ID: 28387939
[TBL] [Abstract][Full Text] [Related]
19. A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation.
Aldinucci A; Gerlini G; Fossati S; Cipriani G; Ballerini C; Biagioli T; Pimpinelli N; Borgognoni L; Massacesi L; Moroni F; Chiarugi A
J Immunol; 2007 Jul; 179(1):305-12. PubMed ID: 17579050
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials.
Zaremba T; Thomas H; Cole M; Plummer ER; Curtin NJ
Cancer Chemother Pharmacol; 2010 Sep; 66(4):807-12. PubMed ID: 20490796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
